Three important and essential fetal scans are recommended
during pregnancy. One at 12-14 weeks of gestation known as NT scan, one at 20
weeks of gestation known as morphology scan and a third one at 28 weeks of
gestation known as Doppler scan. A respect of these dates is fundamental to be
able to detect specific fetal features.
The first scan is the Nuchal Translucency scan (NT scan =
thickness of the fluid at the back of the neck of your baby). It is performed
from 12 up to 14 weeks. During this scan fetal specialist will check for fetal
heart beats, total length of the baby, nuchal translucency and presence of
nasal bone. The accuracy of this scan is from 60-65% only. However, to increase
a little bit the accuracy of this scan we usually perform a blood test with the
scan.
Two different options exist for this blood test, the first
one is to do biochemical test. It is a blood sample in which we are detecting
the levels of two placental hormones {Free Beta Human Chorionic Gonadotropin
(FBHCG) and Pregnancy Associated Plasma Protein-A (PAPP-A)}. Both hormonal
levels are used to determine the condition of the placenta. Moreover, the
biochemical risk and the ultrasound risk will be used together to determine the
combined risk for major common chromosomal anomalies (trisomy 21, 18 and 13).
This combined risk has a sensitivity of 90-92%.
Another possible blood test during this visit is Non
Invasive prenatal test (NIPT). This test will detect cell free fetal DNA
fragments coming from fetal chromosomes (Chromosomes 13, 18, 21 and sex
chromosomes) and circulating in maternal blood. Its sensitivity varies from
97-99%. It is considered as a screening test but has a high accuracy. It is usually
recommended with advanced maternal age (above 35 years old mothers) and when
mild fetal variations are detected by NT scan.
If major fetal anomalies are detected in the NT scan, an
invasive prenatal test is recommended in order to obtain a piece of the
placenta or some of the amniotic fluid and do fetal genetic analyses according
to the ultrasound findings.
Dr.
Azza Abd El Moneim Attia Mohamed
French Board
Consultant
Clinical Genetics
No comments:
Post a Comment